[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pneumonia-community-acquired\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pneumonia-community-acquired":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100562348","cardiovascular-disease-progression-in-survivors-of-community-acquired-pneumonia-and-lung-infection-by-covid-19-100562348",false,"NCT06601998","Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.","A Non-interventional, Prospective, Cross-sectional Study of Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Sars-Cov-2","HOMI-LUNG CAP","Inclusion Criteria:\n\nGroup A (healthy controls)\n\n1. Adults (18 years or more) of both genders (Female\u002FMale: 50\u002F50 ratio)\n2. No history of severe pneumonia (sCAP, COVID-19 or HAP)\n3. Presence of no or one of the following comorbidities: obesity (defined as body mass index over 35 kg\u002Fm2), type 2 diabetes mellitus, hypercholesterolemia, essential arterial hypertension, or familial history of CVD.\n\nGroup B (CVRD controls)\n\n1. Adults (18 years or more) of both genders (Female\u002FMale ratio: 50\u002F50)\n2. No history of severe pneumonia (sCAP, COVID-19 or HAP)\n3. At least two of the following comorbidities: obesity (defined as body mass index over 35 kg\u002Fm2), type 2 diabetes mellitus, hypercholesterolemia, essential arterial hypertension, or familial history of CVD\n\nGroup C (COVID-19 survivors)\n\n1. Adults (18 years or more) of both genders (Female\u002FMale ratio: 50\u002F50)\n2. Survivors from severe COVID-19 pneumonia at hospital discharge; all patients had consolidation in chest X-ray or chest computed tomography during acute infection and were treated for pneumonia\n3. SoC treatment for acute COVID-19 with dexamethasone\n\nGroup D (sCAP survivors)\n\n1. Adults (18 years or more) of both genders\n2. Survivors from sCAP pneumonia; these patients may be either hospitalized in the ward with pO2FiO2 ratio less than 300 or require admission and hospitalization in the Intensive Care Unit.\n3. SoC treatment for sCAP with antibiotics\n\nExclusion Criteria:\n\nGroup A (healthy controls)\n\n1. Presence of two or more comorbidities\n2. Any other co-existing disorder generating CVRD symptoms\n3. Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians\n4. Pregnancy or lactation\n\nGroup B (CVRD controls)\n\n1. Any other co-existing disorder generating CVRD symptoms\n2. Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians\n3. Pregnancy or lactation\n\nGroup C (COVID-19 survivors)\n\n1. Medical history of severe congestive heart failure (Stage III-IV)\n2. Medical history of stage III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19\n3. Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians\n4. Pregnancy or lactation\n\nGroup D (sCAP survivors)\n\n1. Medical history of severe congestive heart failure (Stage III-IV)\n2. Medical history of stage III or IV dyspnoea according to the New York Heart Association classification before the sCAP\n3. Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians\n4. Pregnancy or lactation",true,"ALL","18 Years",{"count":21,"type":22},650,"ESTIMATED","OBSERVATIONAL","Pneumonia, which can be acquired in the community (including influenza and COVID-19), is a leading cause of mortality. The risk of severe cardiovascular diseases events (stroke, myocardial infarction, pulmonary embolism) increases after infections, but causal mechanisms are not understood yet. There is an essential need for improved understanding of the relationship between pneumonia and cardiovascular diseases and early identification of patients at risk of cardiovascular events to develop tailored therapies.\n\nThe overall concept underpinning \"Homi-lung\" is to investigate the time course of host-microbiome interactions during \\& after pneumonia to i) understand the causal relationship between trained immunity, microbiome dysbiosis and cardiovascular and respiratory diseases (CVRD) progressions, ii) define endotypes of pneumonia associated with response to treatment \\& CVRD history; iii) develop biomarkers to predict the individual response to the treatment \\& CVRD progression, and iv) preclinically validate therapeutical approaches for CVRD during \\& after pneumonia.",[26,27,28],"Pneumonia, Community-Acquired","COVID-19 Pneumonia","Cardiovascular Diseases",[30,31,32,33,34,35,36,37,38],"Covid-19","SARS-CoV-2","Lung infection","Cardiovascular disease","Respiratory disease","Endotypes","Biomarkers","Cardiorespiratory","Economic cost","RECRUITING","2026-06-09",{"date":42,"type":43},"2026-06-10","ACTUAL",{"date":45,"type":43},"2024-11-08",{"date":47,"type":22},"2028-06-08",{"name":49,"class":50},"Hellenic Institute for the Study of Sepsis","OTHER",18,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":5},"100577884","phase-4-efficacy-and-safety-of-faropenem-in-bangladeshi-adult-patients-with-community-acquired-bacterial-pneumonia-cabp-100577884","NCT06804096","Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)","Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP): A Randomized Controlled Trial","Inclusion Criteria:\n\n* Male or female patients aged between 18 to 65 years.\n* Have an acute illness (less than or equal to 7 days duration) with any of the following signs and symptoms consistent with a lower respiratory tract infection (new or worsening):\n\n  1. Fever (body temperature \\> 38.0 °C (100.4 °F) measured orally)\n  2. Shortness of breath\n  3. New onset or increased cough with or without sputum production.\n  4. Chest pain.\n* Have radiographically documented bacterial pneumonia:\n\n  1. Infiltrates in a unilateral, lobar distribution\n  2. Diffuse opacities or white condensed area\n  3. The alveoli fill with white inflammatory fluid\n\nExclusion Criteria:\n\n* Patients with severe pneumonia (Clinical \\& Radiological Assessment)\n* Patients with suspicion of viral pneumonia (bilateral, patchy opacities, etc., in chest radiography.)\n* Patients with suspicion of nosocomial pneumonia, aspiration pneumonia, etc.\n* History of hypersensitivity, known or suspected contraindications, or intolerance to any of the study drugs.\n* Intake of an antibiotic within the last 48 hours before study admission.\n* History of hospitalization within the last 28 days.\n* Patients in pregnancy and lactational state.\n* Patients with Renal impairment (screening eGFR \\\u003C 30mL\u002Fmin).\n* Significant hepatic impairment (Alanine aminotransferase \\> three times the upper limit of normal).\n* Serious diseases that affect the immune system, such as Acquired Immunodeficiency Syndrome (AIDS), cancer, etc.\n* Patients who are taking steroid medications, at least 20 mg daily dose of prednisolone (or equivalent doses of other glucocorticoids).\n* Patients who are accepting chemotherapy or anti-cancer therapy or plan to receive such treatment during the trial or six months prior to enrollment.\n* Had epilepsy, stroke, or other central nervous system disorders or uncontrolled psychiatric history.","65 Years",{"count":61,"type":22},160,"INTERVENTIONAL",[64],"PHASE4","The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP). Eligible participants will be randomly assigned to one of two treatment arms. The first arm will receive faropenem at a dosage of 200 mg administered three times daily for a duration of seven days. The second arm will receive co-amoxiclav 625 mg, also three times daily, along with clarithromycin 500 mg, administered twice daily for seven days. All participants included in the study will undergo follow-up assessments over a period of four weeks. This research aims to provide valuable insights regarding the potential role of faropenem, thereby enhancing clinical outcomes and informing antibiotic stewardship in a region significantly burdened by CABP and characterized by limited treatment alternatives.",[26,67],"Bacterial Pneumonia",[69,70],"CABP","Faropenem","2025-07-09",{"date":73,"type":43},"2025-07-11",{"date":75,"type":43},"2025-02-20",{"date":77,"type":22},"2025-12-01",{"name":79,"class":80},"Dr. Md. Alimur Reza","INDUSTRY"]